The scope of the experimental use exemption is a vital issue for both research-based
and generic pharmaceutical companies. Ina Schreiber and Cyra Nargolwalla of
Cabinet Plasseraud examine attempts to harmonize the law in Europe, and compare
practice in France, Germany and the UK
Unlock this article.
The content you are trying to view is exclusive to our subscribers.